Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 497-502

  Nishida, Clinton R ^a   Lee, Melody ^a   Ortiz De Montellano, Paul R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE; CYTOCHROME P2S1; CYTOCHROME P2W1; CYTOCHROME P450; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; RETINOIC ACID; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BANOXANTRONE; ENZYME INHIBITOR; OXIDE; PRODRUG;

ARTICLE; CELL HYPOXIA; DRUG ACTIVATION; DRUG STRUCTURE; ENZYME ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; ULTRAVIOLET SPECTROSCOPY; ANOXIA; HUMAN; METABOLISM; NEOPLASMS;

ANOXIA; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; OXIDES; PRODRUGS;

EID: 77956241061     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065045     Document Type: Article

References (32)

1. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, et al. (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14:1096-1104.
2. Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, and Yasui W (2006) Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25:2546-2557.
3. Brown JM (1999) The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863-5870.
4. Bui PH and Hankinson O (2009) Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli. Mol Pharmacol 76:1031-1043.
5. Bui PH, Hsu EL, and Hankinson O (2009) Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene. Mol Pharmacol 76: 1044-1052.
6. Dix TA, Fontana R, Panthani A, and Marnett LJ (1985) Hematin-catalyzed epoxidation of 7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by polyunsaturated fatty acid hydroperoxides. J Biol Chem 260:5358-5365.
7. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, and Murray GI (2005) Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11:7369-7375.
8. Eling T, Boyd J, Reed G, Mason R, and Sivarajah K (1983) Xenobiotic metabolism by prostaglandin endoperoxide synthetase. Drug Metab Rev 14:1023-1053.
9. Gevantman LH (2007) Solubility of selected gases in water, in CRC Handbook of Chemistry and Physics, 88th ed (Lide DR ed) pp 80-83, CRC Press, Boca Raton, FL.
10. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, and Ingelman-Sundberg M (2007) Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8:1315-1325.
11. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed (Ortiz de Montellano PR ed) pp 377-530, Kluwer Academic/Plenum, New York.
12. Jang YJ, Cha EY, Kim WY, Park SW, Shon JH, Lee SS, and Shin JG (2007) CYP2S1 gene polymorphisms in a Korean population. Ther Drug Monit 29:292-298.
13. Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, Bernal ML, Ramón y Cajal S, Johansson I, and Ingelman-Sundberg M (2006) Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341:451-458.
14. Karlgren M, Miura S, and Ingelman-Sundberg M (2005) Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 207:57-61.
15. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, and Murray GI (2005) Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 11:3758-3765. (Pubitemid 40685593)
16. Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, and Henner WD (2007) Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin Cancer Res 13:2216-2225.
17. Lee KA, Roth RA, and LaPres JJ (2007) Hypoxia, drug therapy and toxicity. Pharmacol Ther 113:229-246.
18. Nishida CR and Ortiz de Montellano PR (2008) Reductive heme-dependent activation of the N-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem 51:5118-5120.
19. Papadopoulou MV and Bloomer WD (2003) NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9:5714-5720.
20. Patterson LH (2002) Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34:581-592.
21. Patterson LH, Craven MR, Fisher GR, and Teesdale-Spittle P (1994) Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res 6:533-538.
22. Raleigh SM, Wanogho E, Burke MD, McKeown SR, and Patterson LH (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 42:763-767.
23. Rivera SP, Wang F, Saarikoski ST, Taylor RT, Chapman B, Zhang R, and Hankinson O (2007) A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of P4502S1 by both dioxin and hypoxia. J Biol Chem 282:10881-10893.
24. Rota C, Barr DP, Martin MV, Guengerich FP, Tomasi A, and Mason RP (1997) Detection of free radicals produced from the reaction of cytochrome P450 with linoleic acid hydroperoxide. Biochem J 328:565-571.
25. Seow HA, Penketh PG, Shyam K, Rockwell S, and Sartorelli AC (2005) 1,2- Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl] hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA 102:9282-9287.
26. 5. Arch Biochem Biophys 348:107-115.
27. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, and Ibbotson SH (2003) Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361:1336-1343.
28. Smith PJ, Blunt NJ, Desnoyers R, Giles Y, and Patterson LH (1997) DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 39:455-461.
29. Tanabe K, Zhang Z, Ito T, Hatta H, and Nishimoto S (2007) Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org Biomol Chem 5:3745-3757.
30. Tomasz M (1995) Mitomycin C: small, fast and deadly (but very selective). Chem Biol 2:575-579.
31. Wu ZL, Sohl CD, Shimada T, and Guengerich FP (2006) Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69:2007-2014.
32. Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, and Robson T (2006) Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 13:598-605.